Literature DB >> 21755297

Multicenter study evaluating factors for stent patency in patients with malignant biliary strictures: development of a simple score model.

Petra G A van Boeckel1, Ewout W Steyerberg, Frank P Vleggaar, Marcel J M Groenen, Ben J M Witteman, Bas L A M Weusten, Han Geldof, Adriaan C I T L Tan, Marina J A L Grubben, Jan Nicolai, Peter D Siersema.   

Abstract

BACKGROUND: Self-expanding metal stents (SEMS) are known to have a significantly higher patency rate than plastic stents. We aimed to identify prognostic factors, besides stent type, for stent patency and to develop a score model that could further aid in guiding stent choice for the palliation of a malignant biliary stricture.
METHODS: A retrospective multicenter study was conducted. Data on consecutive patients who had a stent placed between January 2002 and July 2009 were collected. Cumulative stent occlusion rates were analyzed by Kaplan-Meier curves and log rank testing, and prognostic factors were assessed by Cox regression analysis.
RESULTS: A total of 690 stents (512 plastic stents, 174 SEMS) were endoscopically placed in 390 patients. At 8 weeks, stent occlusion had occurred in 32% of the plastic stents and 11% of the SEMS. Multivariate analysis indicated that plastic stents (hazard ratio [HR] 2.5, 95% confidence interval [CI] 1.9-3.5), a tight stricture requiring preceding dilation (HR 1.8, 95% CI 1.3-2.5), and a high initial bilirubin level (>50 μmol/L (HR 1.3, 95% CI 1.0-1.7) were independently associated with an increased risk of stent occlusion. A score model based on these 3 factors was able to distinguish between stent procedures with a relatively high and low risk of stent occlusion (median 14 vs. 26 weeks, respectively).
CONCLUSION: Besides plastic stents, stricture severity requiring preceding dilation, and initial higher bilirubin level were associated with a shorter period of stent patency. A simple score model based on these factors was able to predict stent occlusion and may aid in choosing the most appropriate stent type in individual patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755297     DOI: 10.1007/s00535-011-0383-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection.

Authors:  Ewout W Steyerberg; Marjolein Y V Homs; Annemieke Stokvis; Marie-Louise Essink-Bot; Peter D Siersema
Journal:  Gastrointest Endosc       Date:  2005-09       Impact factor: 9.427

2.  Hydrophilic hydromer-coated polyurethane stents versus uncoated stents in malignant biliary obstruction: a randomized trial.

Authors:  G Costamagna; M Mutignani; G Rotondano; L Cipolletta; L Ghezzo; A Foco; A Zambelli
Journal:  Gastrointest Endosc       Date:  2000-01       Impact factor: 9.427

3.  Prospective study of biliary strictures to determine the predictors of malignancy.

Authors:  V G Bain; N Abraham; G S Jhangri; T W Alexander; R C Henning; M E Hoskinson; C G Maguire; E A Lalor; D C Sadowski
Journal:  Can J Gastroenterol       Date:  2000-05       Impact factor: 3.522

4.  The role of bacteria in the blockage of biliary stents.

Authors:  J W Leung; T K Ling; J L Kung; J Vallance-Owen
Journal:  Gastrointest Endosc       Date:  1988 Jan-Feb       Impact factor: 9.427

5.  Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis.

Authors:  K G Yeoh; M J Zimmerman; J T Cunningham; P B Cotton
Journal:  Gastrointest Endosc       Date:  1999-04       Impact factor: 9.427

6.  Metallic stents in malignant biliary obstruction: prospective long-term clinical results.

Authors:  B H Lee; D H Choe; J H Lee; K H Kim; S Y Chin
Journal:  AJR Am J Roentgenol       Date:  1997-03       Impact factor: 3.959

7.  Adjuvant therapies using biliary stenting for malignant biliary obstruction.

Authors:  Y Miura; I Endo; S Togo; H Sekido; K Misuta; Y Fujii; T Kubota; K Tanaka; K Nagahori; H Shimada
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

8.  "Tannenbaum" Teflon stents versus traditional polyethylene stents for treatment of malignant biliary stricture.

Authors:  Marc F Catalano; Joseph E Geenen; Glen A Lehman; Jerome H Siegel; Leslie Jacob; Matthew J McKinley; Isaac Raijman; Peter Meier; Ira Jacobson; Richard Kozarek; Firas H Al-Kawas; Simon K Lo; Kulwinder S Dua; John Baille; Gregory G Ginsberg; William Parsons; Scott M Meyerson; Seth Cohen; Douglas B Nelson; James D McHattie; David L Carr-Locke
Journal:  Gastrointest Endosc       Date:  2002-03       Impact factor: 9.427

9.  Endoscopic management of occluded biliary Wallstents: a cancer center experience.

Authors:  Jack Thomas Bueno; Hans Gerdes; Robert C Kurtz
Journal:  Gastrointest Endosc       Date:  2003-12       Impact factor: 9.427

Review 10.  Plastic or expandable biliary endoprostheses?

Authors:  K Huibregtse
Journal:  Scand J Gastroenterol Suppl       Date:  1993
View more
  4 in total

1.  Risk Factors for the Development of Stent-Associated Cholangitis Following Endoscopic Biliary Stent Placement.

Authors:  Brendan T Everett; Shelly Naud; Richard S Zubarik
Journal:  Dig Dis Sci       Date:  2019-02-20       Impact factor: 3.199

Review 2.  Palliative Percutaneous Biliary Interventions in Malignant High Bile Duct Obstruction.

Authors:  Amy R Deipolyi; Anne M Covey
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

3.  Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer.

Authors:  Jinwoo Ahn; Dong-Won Ahn; Jaewoo Park; Kwangrok Jung; Jong-Chan Lee; Jin-Hyeok Hwang; Ji Bong Jeong; Jaihwan Kim
Journal:  J Gastrointest Oncol       Date:  2022-08

4.  Predictors for occlusion of the first inserted metallic stent in patients with malignant biliary obstruction.

Authors:  Wandong Hong; Yunfei Zhu; Yanyan Dong; Yanqing Wu; Mengtao Zhou; Haizhen Ni
Journal:  Saudi J Gastroenterol       Date:  2015 Nov-Dec       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.